HC Wainwright & Co. Downgrades Soleno Therapeutics to Neutral, Lowers Price Target to $53

Soleno Therapeutics Inc +0.23% Pre

Soleno Therapeutics Inc

SLNO

52.63

52.63

+0.23%

0.00% Pre
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Soleno Therapeutics (NASDAQ: SLNO) from Buy to Neutral and lowers the price target from $100 to $53.